Therefore, inhibiting SCF-SKP2 for p27 stabilization recognition may be more beneficial for a therapeutic approach in MPD/CML and other hematological malignancies. The gene discussed is SKP2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.